Part B vs. Part D Billing: Avoid the Specialty Drug Cost Trap

A patient arrives for an expensive injectable treatment and tells the front desk, “My Medicare drug costs are capped now.” The statement may be correct for the patient’s Part D prescriptions—and completely wrong for the medication the practice is about to administer. If that distinction is discovered after treatment, the practice has more than a collection problem. It has a benefits-verification failure, an unreliable estimate, and a patient who reasonably believes someone should have explained the difference.

That conversation is especially timely in October 2026. Medicare’s first negotiated prices for selected Part D drugs took effect on January 1, and the annual Part D out-of-pocket threshold is now $2,100. Meanwhile, Medicare’s October 15–December 7 annual enrollment period is approaching. Patients are comparing drug costs, advertisements are emphasizing savings, and practices are preparing for another round of coverage changes.

For specialty practices, the operational challenge is not memorizing a new dollar limit. It is keeping the medical benefit, pharmacy benefit, acquisition channel, and patient estimate aligned. Part B versus Part D billing deserves its own workflow—not a checkbox buried in a generic eligibility response.

1. What changed in 2026—and what did not

The Inflation Reduction Act changed Medicare prescription drug financing in ways patients can feel directly. The Part D annual out-of-pocket threshold, introduced at $2,000 in 2025, increased to $2,100 for 2026. Once an enrollee reaches that threshold through qualifying spending, the enrollee has no additional cost sharing for covered Part D drugs for the remainder of the calendar year.

That is not a universal Medicare spending cap. Part D premiums, noncovered prescriptions, and Part B medical expenses do not become protected by the Part D limit. Nor should a practice assume that the retail price of a prescription equals the amount credited toward the patient’s threshold. Part D uses defined rules for counting qualifying out-of-pocket spending.

The Medicare Drug Price Negotiation Program also reached its first implementation year in 2026, with negotiated prices taking effect for the initial group of ten selected Part D drugs. This is a major change, but it is not a blanket reduction in every specialty medication’s price or every physician-administered drug’s reimbursement.

For a billing office, the practical distinction is simple: lower Part D exposure does not establish lower Part B exposure. Neither a newspaper headline nor a patient’s pharmacy receipt establishes the benefit under which today’s treatment must be billed.

2. Classify the benefit before estimating the bill

Part B generally covers certain drugs furnished in connection with physician services, including many drugs that are not usually self-administered. It also covers specified categories under separate statutory rules. Part D generally covers eligible outpatient prescription drugs that are not payable under Part A or Part B for the particular circumstances in which they are prescribed and furnished.

The phrase “for the particular circumstances” matters. Benefit classification can depend on the drug, its use, how it is administered, the equipment involved, and whether applicable coverage conditions are met. An injection is not automatically Part B. A prescription sent to a pharmacy is not automatically Part D.

Insulin illustrates the problem. Insulin used through a qualifying durable medical equipment pump may fall under Part B, while insulin used through other delivery methods generally falls under Part D. The name of the medication alone does not settle the billing route.

Build a drug-benefit record that answers these questions before acquisition or scheduling:

• What exact product, strength, formulation, dose, and route are ordered?
• Where and by whom will the drug be administered?
• Is coverage being evaluated under Original Medicare, a Medicare Advantage medical benefit, or a Part D benefit?
• Which coverage criteria, self-administered drug rules, or equipment requirements affect classification?
• Which entity will purchase, dispense, administer, and bill for the drug?

3. A denial under one benefit is not approval under the other

One of the most expensive shortcuts in specialty billing is treating a Part B denial as permission to submit the same expense to Part D. The reverse assumption is equally dangerous. A claim can fail because the benefit is wrong, but it can also fail because the indication, documentation, coding, supplier status, or other coverage requirement is wrong.

Consider an office-administered product that a Medicare Administrative Contractor treats as usually self-administered. That classification may affect Part B coverage. It does not establish that a Part D plan will cover the office’s acquisition cost, accept a physician’s medical claim, or reimburse a medication obtained outside the plan’s dispensing arrangements.

Similarly, a pharmacy rejection stating that a drug may belong under the medical benefit is a routing signal, not a medical-benefit authorization. The practice still needs to confirm the applicable coverage and procurement requirements. Simply forwarding the rejection to the infusion scheduler leaves the central question unanswered.

Require staff to distinguish a benefit-classification issue from a coverage denial. Record the actual denial or rejection reason, the source of the decision, and the next accountable party. For an ambiguous case, obtain clarification before the practice purchases the drug. A vague note saying “payer says covered” is not enough to support a high-dollar commitment.

4. Separate the drug claim from the administration service

Drug sourcing can change the practice’s bill without eliminating its work. Under a buy-and-bill arrangement, the practice acquires the medication and, when coverage and billing requirements are met, bills for the drug and associated administration. When a specialty pharmacy supplies a patient-specific dose, the practice may still furnish a separately billable administration service, but it generally should not bill as though it purchased the supplied drug.

This is where pharmacy and medical workflows collide. A payer’s specialty-pharmacy requirement does not by itself tell you which benefit will adjudicate the drug. Likewise, a shipment arriving at the office does not prove that coverage was resolved correctly. Confirm the actual arrangement rather than relying on labels such as “white bagging.”

Keep the sourcing decision visible in both the clinical schedule and charge capture. If the clinical team documents administration while the billing system automatically generates the practice’s usual drug charge, a patient-specific shipment can produce duplicate or unsupported billing.

Reconcile these elements before releasing charges:

• Drug ownership and acquisition source, supported by the purchase record or patient-specific shipment documentation.
• The entity responsible for billing the medication and the entity billing administration.
• The administered dose and billable units, rather than an assumed match between package size and HCPCS units.
• Any discarded-drug reporting requirements that apply to the particular Part B drug claim.
• Applicable authorization, site-of-care, and servicing-provider information for the treatment actually furnished.

5. Build a verification record that survives a handoff

Specialty drug verification often fails between people rather than within a single task. One employee checks eligibility, another obtains authorization, a third orders the medication, and a fourth answers the patient’s cost question. Each person may complete an assigned step while the overall financial picture remains contradictory.

Use one case record for benefit classification, sourcing, authorization, and the estimate. Identify the plan product—not merely the insurer’s brand name. A carrier can administer Medicare Advantage medical coverage, a Part D product, and other insurance, each with different claim routes and requirements.

Capture the effective dates, servicing location, rendering provider, relevant identifiers, authorization scope when required, and the evidence supporting the determination. For a telephone confirmation, retain the date, representative or reference information, and the precise question asked. “Is this drug covered?” is weaker than asking whether the specified product and service are covered under the stated benefit at the intended location.

Practices using outside medical billing services should make ownership explicit. Does the vendor verify benefits, interpret a denial, reconcile the shipment, or only submit the resulting claim? Outsourcing claim submission does not automatically outsource responsibility for deciding whether the practice should buy an expensive drug. The handoff needs a named owner and a stop-work rule for unresolved discrepancies.

6. Explain patient liability without borrowing Part D promises

For many covered physician-administered drugs under Original Medicare, Part B deductible and coinsurance rules apply. Supplemental coverage may pay some or all of the patient’s remaining liability. Medicare Advantage cost sharing depends on the plan and service. None of those amounts should be estimated by importing the $2,100 Part D threshold into the medical benefit.

A useful patient explanation is direct: “Your prescription-drug limit applies to covered Part D medicines. We are checking whether this treatment is billed under your medical coverage instead. We will also check your supplemental coverage before estimating what you owe.” That language acknowledges the patient’s understanding without promising an answer prematurely.

The Medicare Prescription Payment Plan creates another source of confusion. Participating Part D enrollees can spread their out-of-pocket costs for covered Part D drugs over monthly payments billed by their plan. It is a payment-timing option, not a discount or a separate insurance benefit. It does not convert the practice’s Part B receivable into a Part D payment-plan balance.

Finally, an estimate is not permission to collect every amount a system labels “patient responsibility.” Screen for Medicaid and Qualified Medicare Beneficiary protections. QMB beneficiaries cannot be billed for Medicare Part A or Part B deductibles, coinsurance, or copayments. Before collecting, resolve benefit coordination and applicable billing restrictions—not just the arithmetic.

7. Treat fall enrollment as a treatment-continuity project

The annual enrollment period running from October 15 through December 7 generally produces coverage changes effective January 1. For a practice managing recurring injections or infusions, that is a scheduling and inventory deadline as much as an insurance deadline.

A patient can retain the same clinician while changing the rules around the medication. A new plan may have a different formulary, network, preferred specialty pharmacy, authorization process, or site-of-care requirement. An existing authorization should not be assumed to transfer to a different plan. Remaining with the same insurer also does not guarantee an unchanged product or benefit design.

Ask patients with ongoing high-cost treatment to report planned coverage changes as soon as they know them. Review available plan documents, including the Annual Notice of Change when relevant, but do not represent a fall review as final January verification. Updated eligibility and the treatment-specific requirements still need confirmation.

Create a January watchlist rather than forcing every case into a single December scramble:

• Patients with treatment scheduled early in January and any reported insurance change.
• Patients whose medication requires recurring authorization or a designated dispensing channel.
• Cases in which current coverage depends on an exception or other individualized determination.
• Patients changing between Original Medicare and Medicare Advantage.
• Treatments for which an unresolved benefit decision would leave the practice holding expensive inventory.

8. Audit the claim chain, not just the final denial

An effective drug-billing review starts before the claim. Select a manageable sample of recent high-cost treatments and reconstruct the chain from the order through payment. Include paid claims: a paid drug line may still reflect incorrect units, an inappropriate charge for pharmacy-supplied medication, or an inaccurate patient balance.

For each case, compare the clinical order, coverage determination, acquisition documentation, administration record, claim, remittance, and patient ledger. The objective is to identify whether the practice made the right financial decision at the moment it committed to treatment—not merely whether someone eventually persuaded a payer to pay.

Track defects in categories that point to an owner. A sourcing mismatch belongs in procurement and charge capture. An outdated plan record belongs in registration and verification. A correct payer determination that was never communicated belongs in the handoff process. Combining them all under “drug denial” hides the repair.

Useful internal measures include unresolved benefit classifications before scheduled treatment, pharmacy-supplied drugs incorrectly charged as practice inventory, patient estimates revised after administration, and claims delayed while staff locate sourcing documentation. Establish the practice’s own baseline rather than chasing an unsupported industry benchmark. Improvement should mean fewer preventable commitments and cleaner balances, not simply faster claim submission.

9. Put one owner in charge of the drug revenue pathway

The quickest practical improvement is to assign one operational owner to the entire drug revenue pathway. That person does not need to perform every task. They do need authority to stop acquisition when the benefit is unresolved, reconcile conflicting payer information, and ensure that clinical, pharmacy, and billing teams are working from the same facts.

Start with the medications that create the largest financial exposure or the most frequent benefit confusion. Build a short, product-specific checklist, test it against actual cases, and correct the system defaults that generate avoidable charges. Then extend the process to lower-volume therapies. A focused workflow that staff actually use is more valuable than a comprehensive policy stored outside their daily systems.

Enrollment issues also deserve a distinct escalation route. If payment depends on the participation or enrollment status of the treating clinician, group, or location, connect the drug workflow with the team handling provider credentialing services. A valid authorization does not cure an enrollment problem, and a participation issue should not masquerade as a pharmacy-benefit dispute.

Medicare’s 2026 drug changes are meaningful, but their financial protections have boundaries. The practice’s job is to locate those boundaries before treatment, explain them without jargon, and make the claim reflect the actual drug pathway. That is how a promising headline becomes an accurate patient conversation instead of an unexpected bill.